{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-099094","form_type":"8-K","ticker":"OSTX","cik":"0001795091","company_name":"OS Therapies Inc","filed_at":"2024-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.657703+00:00","generated_at":"2026-05-29T23:51:19.369879+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"OS Therapies Q3 net loss $2.9M; Phase 2b osteosarcoma data due Dec 2024","bullets":["Net operating loss $2.875M in Q3 2024 vs $2.006M in Q3 2023; EPS -$0.18 vs -$0.38.","Completed dosing all 41 patients in Phase 2b trial of OST-HER2 in resected recurrent osteosarcoma.","Topline Phase 2b data expected December 2024; seeking FDA Breakthrough Therapy designation.","Company completed IPO in Q3 2024; pre-revenue with future revenue expected from priority review voucher."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-099094","json":"https://secwatch.observer/filing/0001213900-24-099094.json","markdown":"https://secwatch.observer/filing/0001213900-24-099094.md","text":"https://secwatch.observer/filing/0001213900-24-099094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1795091/000121390024099094/0001213900-24-099094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1795091/000121390024099094/ea0221417-8k_osthera.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T23:51:19.369879+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}